Formycon AG and Fresenius Kabi have announced the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada. This product is available in both subcutaneous and intravenous ...

Swissnet Group has unveiled its preliminary unaudited financial results for FY2024, showing significant growth. The Group's revenue reached CHF 13.1 million, marking a 112% increase from CHF 6.2 ...

Swissnet Group has announced its preliminary unaudited financial results for FY2024, showcasing significant growth aligned with previous guidance. The company's revenue reached CHF 13.1 million, ...